Glaucocalyxin B attenuates diabetic cardiomyopathy by suppressing the NLRP3 inflammasome and restoring gut microbiota homeostasis

Puntos clave

• Diabetic cardiomyopathy shows significant improvement with glaucocalyxin B treatment, enhancing heart function.
• A reduction in NLRP3 inflammasome activity was observed, demonstrating its role in heart health.
• Assessment using gut microbiota analysis indicated restoration of microbial balance after treatment.
• This highlights potential for glaucocalyxin B in managing cardiac complications in diabetes.